Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (
TheStreet) -- Jim Cramer hates to talk politics, Washington and especially the fiscal cliff. To him, that's personal stuff.
But when it comes to helping you make money, he has no choice but to handicap whether there will be a deal and must rant on the fiscal cliff.
"Until we get a deal, it's bad news for the market, even for a cheap stock like
, said Cramer. Apple is a holding in Cramer's charitable trust,
Action Alerts PLUS
Cramer says he prefers for stocks to go higher. Without a fiscal cliff deal in Washington, stocks will go lower. He says the Apple sell-off is due to expectations of higher capital gains taxes next year so shareholders are selling before Dec. 31.
If the fiscal cliff issue is settled before then, Cramer says the Apple sell-off will subside.
"I was hoping Congress would be reasonable," Cramer said. "Compromise used to be American way."
Now, any form of fiscal cliff deal would be better than nothing, he said. "The fiscal cliff is moronic," Cramer said, it's being "done with a meat ax." Cramer would like to see the cliff issue resolved over time.
Cramer's not sure cutting all these government programs quickly is the way to get to higher stock prices. But "what would hurt the market most is if we get no deal at all," Cramer said.
Cramer is looking for ways to immunize investors against that a bad economy. What better area than biotech?
(IMGN - Get Report)
presented at the American Society of Hematology conference in Boston data on its next-generation cancer treatment that targets small-cell lung cancer.
The best part, said Cramer, is that not only is this treatment, IMGN 901, targeting lung cancer but it is wholly owned by the company and it will share no royalties on it, as it does with its TVM1 compound under an agreement with Roche.
So far the molecule, used in a compound with two other drugs, is showing "very good response," which is encouraging, said ImmunoGen CEO Daniel Junius. He said the company expects to have 11 cancer compounds in clinical trials by next June.
Junius said the focus right now is on the small-cell lung cancer, a "heinous disease." There are 30,000 new cases of this type of cancer every year, he said, and if the company is successful with IMGN 901 against this disease it could be extended to other types of diseases.
In the Pipeline
(ENB - Get Report)
is the kind of great, long-term, positive story he loves. He spoke with the pipeline operator's President and CEO Al Monaco about the $26 billion worth of fuel pipeline projects the company is working on in North America.
"There's been a huge renaissance in oil production, not just in Canada from the oil sense but also in the U.S., and that's fueling the need for more and more pipeline capacity," Monaco said. "At the end of the day, connecting these markets from growing supply with refinery markets and demand markets means ultimately lower fuel prices for consumers."
North Dakota's Bakken and Williston Basin formation have played a huge role in increasing oil production, Monaco said. The company's runs pipelines from western Canada to the U.S. West Coast, to the Midwest to the Delta area where the refineries are located.
Monaco says he doesn't see gasoline coming back down to $2.50 a gallon, mainly because oil prices are set on the world market. "But you will see better connectivity between supply and demand. That will ensure efficient market pricing for fuel," he added.
Natural gas in North America is selling way below world gas prices. With connectivity and exporting of natural gas, it makes sense to get the world price for natural gas. "Right now we're selling at a huge discount to natural gas as well as oil, in North America," Monaco said.
Monaco said the natural gas pumped from western Canada to the West Coast would feed the demand and be exported to Asian markets.
Cramer said Enbridge is one of the most consistent long-term pipeline stories. And, they keep raising their dividends. He likes it.
In the Lightning Round, Cramer was bullish on
He was bearish on
Northern Tier Energy
Another Type of Pipeline
Continuing with biotechs, Cramer talked to Seattle Genetics CEO Clay Siegall, who also presented data during the American Society of Hematology conference, on the company's Adcetris treatment for Hodgkins lymphoma.
Siegall said the company aims to use antibodies to kill cancer cells without creating toxicity in the body. The newest treatment has showed less toxicity and improved remission rates.
He said the company has a number of drugs in the pipeline that will either be in clinical trials next year or, in the case of Canada, are expected to be approved in 2013 for use.
While acknowledging company sales may be flat next year, Siegall said he is "looking forward to a lot of catalysts" to push sales in the coming year.
Cramer said the current weakness in the company's shares could be a buying opportunity for investors.
No Huddle Offense
What's more American than Tupperware? Well, Cramer said he spoke with
(TUP - Get Report)
CEO Rick Goings earlier Monday on
"Squawk On the Street" and asked him if he would return capital to shareholders in the form of a special dividend. The CEO said the board is pondering just such action.
Indonesia has become Tupperware's best country, with sales up 30% year over year and last year's sales up were up 50% from the year before. About 66% of Tupperware sales come from emerging markets, including India and Latin America.
Cramer said the growth speaks of the product's universality and its acceptance over goods that can be bought in a retail store.
Not only does the company spew cash, Cramer said of Tupperware, but it is a high-quality direct seller that hit a 52-week high today.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Anthony Buccino and Margo D. Beller in New York.